Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06821497 + Enzalutamide vs Enzalutamide or Docetaxel in mCRPC
NCT06551324Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of mevrometostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pfizer. Started Oct 2024; status: active, not recruiting.
02
Drugs
mevrometostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06551324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551324.